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study was designed to determine QoL-based utilities 
speciﬁc to RGH. METHODS: Discrete choice conjoint
analysis (CA) and time trade off (TTO) exercises were
conducted using QoL states generated from six items
from the RGH Quality of Life Questionnaire (RGHQoL).
RGH patients completed tasks via interview. RESULTS:
One hundred ninety-two interviews were conducted (79
male, 113 female; age range 19–69 years, mean age 38.4).
For CA, all attributes were statistically signiﬁcantly inﬂu-
ential in determining preferences. The application of the
random effects probit model produced coefﬁcient values
that can be used as preference weights. For the TTO exer-
cise, coefﬁcient values (preference weights) were derived
by application of the random effects tobit regression
model. These coefﬁcient values can be used to derive rel-
ative and absolute utility values respectively. As the TTO
technique possesses cardinal properties, QALY scores 
can also be calculated. CONCLUSIONS: It is feasible to
generate both relative and absolute utility values from
responses to the RGHQoL questionnaire, allowing utility
to be based on true QoL. The ability to derive disease-
speciﬁc QoL-based utilities in this way means that the
same instrument can be used to generate both QoL and
utility data from the same clinical trial.
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OBJECTIVE: Patients with Alzheimer’s disease (AD)
have progressive cognitive, functional, and behavioral
decline, resulting in increased reliance on caregivers for
assistance with activities of daily living. Galantamine, a
novel treatment for AD with a dual mode of action
(acetylcholinesterase inhibition and allosteric nicotinic
receptor modulation), has demonstrated beneﬁts on cog-
nition, global function, activities of daily living, and
behavioral symptoms in patients with mild-to-moderate
AD. The objective of this study was to determine differ-
ences in caregiving time between caregivers of AD
patients receiving galantamine and those receiving no
treatment. METHODS: The analysis was based on data
from the AD Caregiver Project survey. Data were col-
lected using a self-administered questionnaire distributed
in December 2001 to a large national sample of unpaid
caregivers. Caregiver time was deﬁned as the number of
hours spent by the primary caregiver during a typical
week. Only patients living in the community were
included in the analysis. Using linear regression, caregiv-
ing times for galantamine-treated and untreated patients
were compared. Covariates included patient and care-
giver demographics, including employment status and
income level, and patient disease severity, functional
status, and living situation. RESULTS: Galantamine
patients (N = 97) differed from untreated patients (N =
803) with regard to gender (61% vs 35% males), age
(74.1 vs 79.6 years), and living situation (1% vs 6%
living alone). Caregivers of galantamine patients were
older (66.3 vs 59.2 years) and more likely to be a spouse
(77% vs 33%). After controlling for differences between
the groups, caregivers of galantamine patients provided
18 fewer hours of care per week than caregivers 
of untreated patients (95% CI: 3.3–32.5, p = 0.016).
CONCLUSION: Compared with untreated patients,
patients treated with galantamine appear to require sig-
niﬁcantly less caregiving time.
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OBJECTIVE: To investigate the effect of rivastigmine
treatment on the time to ﬁrst antipsychotic drug use
among patients with Alzheimer’s disease (AD), compared
to patients not treated with a cholinesterase inhibitor
(ChEI). METHODS: This study used MarketScan®
research databases from January 1, 1999 through Decem-
ber 31, 2001. Patient inclusion criteria included: (a) diag-
nosis of AD, (b) ≥65 years old at diagnosis, and (c)
continuous insurance coverage. Patients who previously
used any antipsychotics were excluded. Subjects were
classiﬁed into a ChEI group with the ﬁrst prescription
date as the index date or a non-ChEI group. Patients on
rivastigmine were further identiﬁed from the ChEI group.
Chi-square test, t-test, and log-rank test were used to test
differences in study variables between groups. Cox pro-
portional hazard models were used to estimate predicted
risk of the ﬁrst antipsychotic drug use. RESULTS: A total
of 2391 patients were included in the study (996 ChEI
and 1395 non-ChEI). ChEI users were younger compared
to non-ChEI users (79 vs. 81 years, P < 0.0001). However,
there were no signiﬁcant differences between antipsy-
chotic users and non-users, by age or gender. Over the
entire observation period, Kaplan-Meier analysis indi-
cated that users of ChEIs were 4% (relative risk (RR) =
0.96; 95% CI:0.77–1.18) less likely and patients taking
rivastigmine speciﬁcally (N = 214) were 19% (RR = 0.81;
95% CI:0.54–1.21) less likely to take antipsychotics as
compared to patients not taking ChEIs. After controlling
for demographic covariates, use of other psychotropics
and anticonvulsants, rivastigmine patients were 34% (RR
= 0.66; 95% CI:0.36–1.22) less likely to take antipsy-
